Search Results 71-80 of 16610 for B cell lymphomas
ZUMA-7 led to the approval of axicabtagene ciloleucel for second line treatment of large B-cell lymphoma after showing better outcomes compared with ...
Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study. Print ...
The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B- ...
CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...
Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Share · Facebook · Twitter.
... B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL). Participation eligibility.
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic ...
The white blood cells involved in hairy cell leukemia are called B cells. B ... The other cancers include non-Hodgkin's lymphoma, Hodgkin's lymphoma and others.
Ansell's lymphoma research program, which focuses on the TME and B cell cancer biology, has produced over 450 journal articles, including the 2021 paper in JCO ...
... cell lymphoma, a subset of B-cell lymphoma. It was also approved in February 2014 for use in CLL, following a study of the agent alone in patients with very ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.